Dr. Mark C. Markowski, M.D., PH.D.
Hematology & Oncology (Hematology & Oncology Physician)
600 N Wolfe St
Baltimore, MD 21287
Who else practices at this address →
Baltimore city includes primary care (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Georgetown University School of Medicine (2009)
- Years since graduation
- 17
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 189
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Medical school: Georgetown University School of Medicine
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MD license D74195 -
Internal Medicine Physician
MD license D74195
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Johns Hopkins Hospital, the Baltimore, MD
- Sibley Memorial Hospital Washington, DC
Medical groups
- Johns Hopkins University (2,909 clinicians)
- Johns Hopkins University (197 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 189
- Services billed
- 580
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 392 | 154 |
| New patient office or other outpatient visit, 60-74 minutes | 59 | 59 |
| Established patient office or other outpatient visit, 20-29 minutes | 42 | 33 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 40 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Baltimore, MD | 107 |
| Abiraterone Acetate | 82 |
| Nubeqa (darolutamide) | 40 |
| Tamsulosin Hcl Other prescribers in Baltimore, MD | 26 |
| Bicalutamide | 21 |
| Xtandi (enzalutamide) | 17 |
| Xarelto (rivaroxaban) Other prescribers in Baltimore, MD | 16 |
| Revlimid (lenalidomide) | 13 |
| Dexamethasone Other prescribers in Baltimore, MD | 12 |
| Erleada (apalutamide) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $1,619,473 in research payments for these studies, mostly to the institutions running them.
- A phase 3 randomized efficacy and safety study of enzalutamide plus leuprolide enzalutamide monotherapy and placebo plus leuprolide in men with highrisk nonmetastatic prostate cancer progressing after definitive therapy
Pfizer Inc. - A Pilot, Phase II study of Olaparib in Patients with Advanced, Metastatic Renal Cell Carcinoma with BAP1 and other DNA-Repair Mutations Cancer. (TRAP trial).
AstraZeneca Pharmaceuticals LP - A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Ca…
AstraZeneca Pharmaceuticals LP - A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell…
Exelixis Inc. - A phase 3 randomized efficacy and safety study of enzalutamide plus leuprolide enzalutamide monotherapy and placebo plus leuprolide in men with highrisk nonmetastatic prostate cancer progressing after definitive therapy
Medivation LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.